A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo.
作者信息
Jiang Chao, Mei Miao, Li Bin, Zhu Xiurui, Zu Wenhong, Tian Yujie, Wang Qiannan, Guo Yong, Dong Yizhou, Tan Xu
机构信息
School of Pharmaceutical Sciences, Center for Infectious Disease Research, School of Medicine, Tsinghua University, Tsinghua-Peking Center for Life Sciences, Beijing 100084, China.
Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
出版信息
Cell Res. 2017 Mar;27(3):440-443. doi: 10.1038/cr.2017.16. Epub 2017 Jan 24.
Abstract
摘要
相似文献
1
A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo.
Cell Res. 2017 Mar;27(3):440-443. doi: 10.1038/cr.2017.16. Epub 2017 Jan 24.
2
In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.
Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1741-1747. doi: 10.1161/ATVBAHA.117.309881. Epub 2017 Jul 27.
3
Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome.
J Gen Virol. 2015 Aug;96(8):2252-2261. doi: 10.1099/vir.0.000159. Epub 2015 Apr 22.
4
Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.
Virology. 2015 Feb;476:196-205. doi: 10.1016/j.virol.2014.12.001. Epub 2014 Dec 29.
5
CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.
Arterioscler Thromb Vasc Biol. 2016 May;36(5):783-6. doi: 10.1161/ATVBAHA.116.307227. Epub 2016 Mar 3.
6
CES1-Triggered Liver-Specific Cargo Release of CRISPR/Cas9 Elements by Cationic Triadic Copolymeric Nanoparticles Targeting Gene Editing of PCSK9 for Hyperlipidemia Amelioration.
Adv Sci (Weinh). 2023 Jul;10(19):e2300502. doi: 10.1002/advs.202300502. Epub 2023 Apr 21.
7
CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse.
Virus Res. 2016 Jun 2;217:125-32. doi: 10.1016/j.virusres.2016.04.003. Epub 2016 Apr 2.
8
CRISPR/Cas9 Gene Targeting in Primary Mouse Bone Marrow-Derived Macrophages.
Methods Mol Biol. 2020;2097:223-230. doi: 10.1007/978-1-0716-0203-4_14.
9
An update on using CRISPR/Cas9 in the one-cell stage mouse embryo for generating complex mutant alleles.
Cell Death Differ. 2017 Oct;24(10):1821-1822. doi: 10.1038/cdd.2017.122. Epub 2017 Jul 28.
10
Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
Atherosclerosis. 2016 May;248:62-75. doi: 10.1016/j.atherosclerosis.2016.02.018. Epub 2016 Mar 9.
引用本文的文献
1
Therapeutic interventions aimed at cccDNA: unveiling mechanisms and evaluating the potency of natural products.
Front Cell Infect Microbiol. 2025 Jun 17;15:1598872. doi: 10.3389/fcimb.2025.1598872. eCollection 2025.
2
Dual SORT LNPs for multi-organ base editing.
Nat Biotechnol. 2025 Jun 2. doi: 10.1038/s41587-025-02675-z.
3
Newborn Intravenous Injection of Liposomal CRISPR/Cas9 Complex Has No Incidence of Off-Targets or Tumors in Mice.
Pharmaceutics. 2025 May 17;17(5):656. doi: 10.3390/pharmaceutics17050656.
4
Therapeutic Nanomaterials in NAFLD: Current Advances and Potential Applications in Patients with Concurrent HBV Infection.
Int J Nanomedicine. 2025 Mar 25;20:3803-3823. doi: 10.2147/IJN.S510271. eCollection 2025.
5
Targeting HBV cccDNA Levels: Key to Achieving Complete Cure of Chronic Hepatitis B.
Pathogens. 2024 Dec 13;13(12):1100. doi: 10.3390/pathogens13121100.
6
Engineered PsCas9 enables therapeutic genome editing in mouse liver with lipid nanoparticles.
Nat Commun. 2024 Nov 7;15(1):9173. doi: 10.1038/s41467-024-53418-8.
7
The potential of HBV cure: an overview of CRISPR-mediated HBV gene disruption.
Front Genome Ed. 2024 Oct 9;6:1467449. doi: 10.3389/fgeed.2024.1467449. eCollection 2024.
8
Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia.
Circulation. 2024 Aug 27;150(9):724-735. doi: 10.1161/CIRCULATIONAHA.123.067957. Epub 2024 Aug 26.
9
Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders.
Acta Pharm Sin B. 2024 Jul;14(7):2885-2900. doi: 10.1016/j.apsb.2024.04.015. Epub 2024 Apr 22.
10
An antifouling membrane-fusogenic liposome for effective intracellular delivery in vivo.
Nat Commun. 2024 May 20;15(1):4267. doi: 10.1038/s41467-024-46533-z.
本文引用的文献
1
Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo.
Nat Biotechnol. 2016 Mar;34(3):328-33. doi: 10.1038/nbt.3471. Epub 2016 Feb 1.
2
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era.
Curr Opin Lipidol. 2015 Dec;26(6):511-20. doi: 10.1097/MOL.0000000000000239.
3
Biology and Applications of CRISPR Systems: Harnessing Nature's Toolbox for Genome Engineering.
Cell. 2016 Jan 14;164(1-2):29-44. doi: 10.1016/j.cell.2015.12.035.
4
An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo.
Nano Lett. 2015 Dec 9;15(12):8099-107. doi: 10.1021/acs.nanolett.5b03528. Epub 2015 Nov 6.
5
Targeting hepatitis B virus cccDNA using CRISPR/Cas9.
Antiviral Res. 2015 Nov;123:188-92. doi: 10.1016/j.antiviral.2015.10.004. Epub 2015 Oct 22.
6
HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.
Gut. 2015 Dec;64(12):1972-84. doi: 10.1136/gutjnl-2015-309809. Epub 2015 Jun 5.
7
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus.
Sci Rep. 2015 Jun 2;5:10833. doi: 10.1038/srep10833.
8
Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome.
J Gen Virol. 2015 Aug;96(8):2252-2261. doi: 10.1099/vir.0.000159. Epub 2015 Apr 22.
9
Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
Antiviral Res. 2015 Jun;118:110-7. doi: 10.1016/j.antiviral.2015.03.015. Epub 2015 Apr 3.
10
In vivo genome editing using Staphylococcus aureus Cas9.
Nature. 2015 Apr 9;520(7546):186-91. doi: 10.1038/nature14299. Epub 2015 Apr 1.
Zotero 插件